Development and validation of nomograms to recurrence and survival in patients with early-stage cervical adenocarcinoma

doi:10.1007/s00432-023-05068-4

科研成果详情

题名	Development and validation of nomograms to recurrence and survival in patients with early-stage cervical adenocarcinoma
作者	Wang, Xintao 1; Shi, Wenpei 2; Pu, Xiaowen 1; Hu, Yan3; Chen, Ruiying 1; Zhu, Haiyan 1,3
发表日期	2023-11
发表期刊	Journal of cancer research and clinical oncology 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Cervical adenocarcinoma Nomogram Recurrence Survival
其他关键词	RADICAL HYSTERECTOMY ; CANCER ; PREDICTION ; RISK
摘要	Cervical adenocarcinoma is one of the most common types of cervical cancer and its incidence is increasing. The biological behavior and treatment outcomes of cervical adenocarcinoma (CA) differ from those of squamous cell carcinoma (SCC). We sought to develop a model to predict recurrence and cancer-specific survival (CSS) deaths in CA patients., 131 patients were included in model development and internal validation, and patients from the SEER database (N = 1679) were used for external validation. Multivariable Cox proportional hazards regression analysis was used to select predictors of relapse-free survival (RFS) and CSS and to construct the model, which was presented as two nomograms. Internal validation of the nomograms was performed using the bootstrap resampling method., Age, FIGO (International Federation of Gynecology and Obstetrics) stage, size of the tumor, lymph metastasis and depth of invasion were identified as independent prognostic factors for RFS, while age, FIGO stage, size of the tumor and number of positive LNs were identified as independent prognostic factors for CSS. The nomogram of the recurrence model predicted 2- and 5-year RFS, with optimism adjusted c-statistic of 75.41% and 74.49%. Another nomogram predicted the 2- and 5-year CSS with an optimism-adjusted c-statistic of 83.22% and 83.31% after internal validation; and 68.6% and 71.33% after external validation., We developed and validated two effective nomograms based on static nomograms or online calculators that can help clinicians quantify the risk of relapse and death for patients with early-stage CA.
资助项目	Innovation Program of Shanghai Science and Technology Committee[20Y11914200];Shanghai Municipal Health Commission[202040129];National Natural Science Foundation of China[82272778];
出版者	SPRINGER
ISSN	0171-5216
EISSN	1432-1335
卷号	149 期号:15 页码:13727-13739
DOI	10.1007/s00432-023-05068-4
页数	13
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:001040920400003
收录类别	PUBMED ; SCIE ; SCOPUS
在线发表日期	2023-08
URL	查看原文
Pubmed记录号	37526662
Scopus记录号	2-s2.0-85166335121
通讯作者地址	[Chen, Ruiying]Department of Gynecology,Shanghai First Maternity and Infant Hospital,School of Medicine,Tongji University,Shanghai,China ; [Zhu, Haiyan]Department of Gynecology,Shanghai First Maternity and Infant Hospital,School of Medicine,Tongji University,Shanghai,China
scopus学科分类	Oncology;Cancer Research
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/181787
专题	第一临床医学院（信息与工程学院）、附属第一医院_妇产科学_妇科附属第一医院
通讯作者	Chen, Ruiying; Zhu, Haiyan
作者单位	1.Department of Gynecology,Shanghai First Maternity and Infant Hospital,School of Medicine,Tongji University,Shanghai,China; 2.Clinical Research Unit,Shanghai First Maternity and Infant Hospital,School of Medicine,Tongji University,Shanghai,China; 3.Department of Gynecology,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China
推荐引用方式 GB/T 7714	Wang, Xintao,Shi, Wenpei,Pu, Xiaowen,et al. Development and validation of nomograms to recurrence and survival in patients with early-stage cervical adenocarcinoma[J]. Journal of cancer research and clinical oncology,2023,149(15):13727-13739.
APA	Wang, Xintao, Shi, Wenpei, Pu, Xiaowen, Hu, Yan, Chen, Ruiying, & Zhu, Haiyan. (2023). Development and validation of nomograms to recurrence and survival in patients with early-stage cervical adenocarcinoma. Journal of cancer research and clinical oncology, 149(15), 13727-13739.
MLA	Wang, Xintao,et al."Development and validation of nomograms to recurrence and survival in patients with early-stage cervical adenocarcinoma".Journal of cancer research and clinical oncology 149.15(2023):13727-13739.